Cancer drug trial halted early: AMG 199 shows limited promise in advanced tumors
NCT ID NCT04117958
First seen Oct 31, 2025 · Last updated May 19, 2026 · Updated 28 times
Summary
This early-stage study tested a new drug called AMG 199 in adults with advanced stomach, esophageal, colorectal, or pancreatic cancers that have a specific protein (MUC17). The main goal was to check safety and find the best dose. The trial was stopped early, and only 58 people took part. While it aimed to control tumor growth, it was not designed as a cure, and long-term medication would likely be needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUC17-POSITIVE SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Aichi Cancer Center
Nagoya, Aichi-ken, 464-8681, Japan
-
Amsterdam UMC - location VUmc
Amsterdam, 1081 HV, Netherlands
-
Asan Medical Center
Seoul, 138-736, South Korea
-
City of Hope National Medical Center
Duarte, California, 91010, United States
-
Hospital Clinico Universitario de Valencia
Valencia, Valencia, 46010, Spain
-
Hospital Universitari Vall d Hebron
Barcelona, Catalonia, 08035, Spain
-
Institut Gustave Roussy
Villejuif, 94805, France
-
Klinikum der Universitaet Muenchen Campus Grosshadern
München, 81377, Germany
-
Klinikum rechts der Isar
München, 81675, Germany
-
Landeskrankenhaus Salzburg
Salzburg, 5020, Austria
-
Leids Universitair Medisch Centrum
Leiden, 2333 ZA, Netherlands
-
National Cancer Center Hospital
Chuo-ku, Tokyo, 104-0045, Japan
-
National Cancer Center Hospital East
Kashiwa-shi, Chiba, 277-8577, Japan
-
National Taiwan University Hospital
Taipei, 10002, Taiwan
-
Seoul National University Hospital
Seoul, 03080, South Korea
-
Severance Hospital Yonsei University Health System
Seoul, 03722, South Korea
-
Taipei Veterans General Hospital
Taipei, 11217, Taiwan
-
Universitaetsklinikum Hamburg Eppendorf Onkologisches Zentrum
Hamburg, 20246, Germany
-
Universitaetsklinikum Leipzig
Leipzig, 04103, Germany
-
University of California at Irvine Medical Center
Orange, California, 92868, United States
-
Wake Forest University Health Sciences
Winston-Salem, North Carolina, 27157, United States
Conditions
Explore the condition pages connected to this study.